Sunday, November 22, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
Top storiesBack PageHow to earnLeaderboard
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyGTA WeekHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsLeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundHolder perksRobinhood Chain launchesRobinhood Chain projectsList your projectPremium project pagesPartnersThe Chain WeeklyRobinhood Chain Daily
PaparazziPaparazzi InkPaparazzi Ink top writersOpinionLive coverageEvents calendarThe Back PageSuggest a Back Page storyPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyTerms of serviceCorrectionsAccuracy recordRelease notesAdvertiseMedia kitNews APIContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 55
Confirmed by 2 outlets

Alnylam Notches Seventh FDA Approval as Livsayis Clears Myasthenia Gravis

Alnylam Pharmaceuticals has logged its seventh FDA-approved RNAi therapy, with Livsayis greenlit for anti-acetylcholine receptor positive generalized myasthenia gravis. Regeneron develops and sells the drug, so Alnylam collects a $25m approval milestone plus tiered royalties reaching 15% on global net sales.

By the Paparazzi desk November 21, 2026 · 11:09 AM · Sources: 2 outlets · 1 view
Fact boxTrust 58/100 · Developing
What we verified
  • 2 sources report it: simplywall.st, ad-hoc-news.de.
  • The source published it on Nov 21, 2026 at 11:09 AM.
What we couldn't

Nothing open. Every check passed.

Livsayis became the seventh RNAi therapy built on Alnylam Pharmaceuticals' platform to win FDA approval, according to Simply Wall St. The drug is cleared for anti-acetylcholine receptor positive generalized myasthenia gravis, a neuromuscular autoimmune condition. Regeneron develops and commercializes the product, meaning Alnylam's role is financial rather than commercial.

That role comes with a US$25m approval milestone and tiered royalties of up to 15% on global net sales. The approval pushes Alnylam's RNAi platform past rare disease and into broader neurological territory, giving the company exposure to a condition well outside its transthyretin focus.

Sponsored

Simply Wall St notes the win adds another proof point for a pipeline that spans rare, specialty and prevalent diseases. It does not, however, directly loosen Alnylam's reliance on its TTR franchise or the pricing and access risks tied to it. Simply Wall St's narrative maps these catalysts to a $300 fair value for the stock.

The first real read on traction arrives in coming quarterly filings: Regeneron's reported Livsayis sales and the matching royalty line on Alnylam's books. Steady growth in global net sales there would show the drug is gaining ground in its approved myasthenia gravis population.

TopicsAlnylam Pharmaceuticals · ALNY · Livsayis · Regeneron · FDA · RNAi

Share

Written by AI from verified reporting.

More stories

  • Health & science 05:17 UTC · 2 hours ago · sciencealert.com · Caught by @ajayy30 · 1 view
    Kids With More Screen Time Scored Better on Teen Brain Tests, 8-Year Study Finds
  • Health & science 05:08 UTC · 2 hours ago · sciencealert.com · Caught by @ajayy30 · 1 view
    Cockroaches Are Pollinating an Amazon Shrub After Dark, Study Finds
  • Health & science 16:01 UTC · 15 hours ago · breakingthenews.net · 1 view
    Russia presses Kazakhstan for answers on 'decimating virus'
  • Health & science 15:37 UTC · 15 hours ago · independent.co.uk · Caught by @adihidayat · 2 views
    Wolbachia mosquitoes slash dengue infections by 69% in Brazil study
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.